5-Amino-1MQ vs MOTS-c

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

✅ Stacking Partners — These compounds are commonly used together and may have synergistic effects.
⚠️ Known Interactions
LOW Complementary mechanisms — the 5-Amino-1MQ + MOTS-c fat loss stack targets NNMT and AMPK pathways respectively.
LOW Complementary fat loss stack — MOTS-c for AMPK/exercise mimicry, 5-Amino-1MQ for NNMT/NAD+.
5-Amino-1MQMOTS-c
CategoryPeptidesPeptides
Standard DoseResearch indicates 50-150 mg daily via oral administration, typically divided into 1-2 doses.Research indicates 5-10 mg administered 3-5 times per week via subcutaneous injection.
TimingMorning dosing preferred. Can be taken with or without food.Morning administration preferred. Can be dosed pre-workout for enhanced exercise performance.
Cycle Duration8-12 week cycles.8-16 week cycles.
Evidence Levelanimal_plus_anecdotalEmerging (strong preclinical)
A

5-Amino-1MQ

Peptides

Mechanism

5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, generating 1-methylnicotinamide (1-MNA). By inhibiting NNMT, 5-Amino-1MQ increases intracellular NAD+ levels, reduces 1-MNA production, suppresses lipogenesis in adipocytes, and modulates the methionine-homocysteine cycle. In vivo, it significantly reduces body weight, white adipose mass, and adipocyte size through enhanced energy expenditure and altered lipid metabolism.

Standard Dosing

Research indicates 50-150 mg daily via oral administration, typically divided into 1-2 doses.

Timing

Morning dosing preferred. Can be taken with or without food.

Cycle Duration

8-12 week cycles.

Side Effects

  • Mild GI discomfort
  • Headache
  • Diarrhea (uncommon)
  • Nausea at higher doses

Contraindications

  • Pregnancy and breastfeeding
  • Severe hepatic impairment
  • Active cancer (NAD+ modulation concern)

Best Stacking Partners

MOTS-cAOD-9604TesofensineSemaglutide
B

MOTS-c

Peptides

Mechanism

MOTS-c is a 16-amino acid mitochondrial-derived peptide encoded by the 12S rRNA gene of the mitochondrial genome. It primarily acts through the folate-AICAR-AMPK pathway: by regulating the folate cycle and de novo purine biosynthesis, it increases AICAR accumulation, which phosphorylates and activates AMPK. This enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and mimics exercise-mediated physiological responses. Skeletal muscle MOTS-c levels increase 11.9-fold in response to acute exercise in young men.

Standard Dosing

Research indicates 5-10 mg administered 3-5 times per week via subcutaneous injection.

Timing

Morning administration preferred. Can be dosed pre-workout for enhanced exercise performance.

Cycle Duration

8-16 week cycles.

Side Effects

  • Injection site reactions
  • Mild fatigue post-injection
  • Transient flushing
  • Muscle soreness (exercise-mimetic effect)

Contraindications

  • Pregnancy and breastfeeding
  • Type 1 diabetes (insulin sensitivity changes require monitoring)
  • Not FDA-approved
  • Limited human safety data
  • Active cancer (metabolic pathway activation)

Best Stacking Partners

5-Amino-1MQAOD-9604Semaglutide

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →